Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (Nasdaq: QSI) held an Investor & Analyst Day on November 19, 2025 to present updates on the Proteus™ platform and the company’s technology pipeline.
Management reported completion of sequencing on a Proteus prototype, more than 50 sequencing runs across multiple prototypes, and early prototype data that the company says is meeting or exceeding the performance of its Platinum® Pro system. Presentations will describe a long-term roadmap to billions of reads, the path to detecting all 20 amino acids, a suite of post-translational modification (PTM) methods in development, and the path to Proteus commercial launch including timeline and key technical and commercial milestones.
Quantum-Si (Nasdaq: QSI) reported third quarter 2025 results and product progress on November 5, 2025. Q3 revenue was $552,000 with gross profit $194,000 (35% margin); nine‑month revenue was $2.0M with 52% gross margin. The company reported net loss of $35.7M in Q3 and adjusted EBITDA of -$20.1M. Total operating expenses rose to $40.0M in Q3. Quantum‑Si achieved successful sequencing on a prototype Proteus system and remains on track for a Proteus platform delivery in H2 2026. The company launched a version 4 Sequencing Kit in early September and expects a version 3 Library Prep Kit before year‑end 2025. Cash and investments were $230.5M, stated to fund operations into Q2 2028.
Quantum-Si (Nasdaq: QSI) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 at the Westin NY Grand Central in New York.
CEO Jeff Hawkins will take part in a Fireside Chat at 3:30 PM ET on November 20, 2025; Hawkins and CFO Jeff Keyes will be available for one-on-one investor meetings that day. A live and archived webcast will be posted in the Investors > Events & Presentations section of the Quantum-Si website.
Quantum-Si (Nasdaq: QSI) will report third quarter 2025 financial results on Wednesday, November 5, 2025. Management will host a conference call the same day at 4:30 PM ET to discuss results and provide a business update.
Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host the call. Investors may listen via the live webcast on the company's Investors website under Events and Presentations or register to receive a dial-in number and personalized PIN. An archived webcast will be available for replay after the event.
Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein detection, has announced an upcoming Investor & Analyst event scheduled for November 19, 2025 in New York City.
The event will feature presentations from key management team members, followed by a Q&A session. While the in-person event at the Hyatt Centric Times Square is by invitation, a live webcast will be available for virtual attendees from 10 AM to 12 PM ET.
Quantum-Si (Nasdaq: QSI), a proteomics technology company, has granted 17,033 restricted stock units (RSUs) to new employees as inducement awards under its 2023 Inducement Plan. The RSUs will vest over four years, with 25% vesting on September 20, 2026, followed by 12 quarterly installments, contingent on continued employment.
These equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and are specifically designed to attract new talent who were not previously Quantum-Si employees.
Quantum-Si (Nasdaq: QSI) has launched its new V4 Sequencing Kit, compatible with both Platinum® and Platinum® Pro instruments. The upgraded kit delivers an 85% increase in sequenceable peptides compared to the V3 version, featuring enhanced glycine recognition and improved alanine and serine detection capabilities.
Key advancements include the ability to sequence through proline-rich domains, expanded amino acid coverage, and improved sample mixture precision with 24-plex barcoding capabilities. The new kit particularly benefits antibody sequencing applications and complex mixture analysis in immunoprecipitation workflows.
Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein analysis, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place at the Lotte New York Palace Hotel from September 8-10, 2025.
The company's leadership, including President and CEO Jeff Hawkins and CFO Jeff Keyes, will conduct one-on-one meetings on September 9, 2025. Additionally, Jeff Hawkins will participate in a fireside chat at 10:00 AM ET on the same day. Investors can access the live and archived webcast through the company's website in the Investors section.
Quantum-Si (Nasdaq: QSI), a proteomics technology company, has announced the granting of 237,068 restricted stock units (RSUs) to new employees as inducement awards. The grants were made under the company's 2023 Inducement Equity Incentive Plan and approved by the Compensation Committee of QSI's Board of Directors.
The RSUs will follow a vesting schedule with 25% vesting on September 20, 2026, followed by the remaining amount vesting in 12 equal quarterly installments. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are specifically designed for new hires who were not previously QSI employees.
Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein detection, announced its participation in the upcoming UBS Precision Medicine Frontiers Summit. The event will take place at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA, from August 13-14, 2025.
CEO Jeff Hawkins and CFO Jeff Keyes will be available for one-on-one meetings on August 14. Additionally, Jeff Hawkins will participate in the New Dimensions in Proteomics and Cellular Research panel from 8:15 - 8:50 AM PDT on the same day.